Desmopressin (1-desamino-8-D-arginine vasopressin; dDVAP) is a synthetic and
generically available antidiuretic peptide hormone that has been marketed for the treatment …

Drug repurposing is at the heart of precision oncology. The move from tissue-or cancer-
specific treatments to genomic-or actionable-target treatments necessarily entails the reuse …

In today's fast-paced society, efficiency is critical in many aspects, especially in costly,
resourceintensive processes such as drug discovery and development. Technological …

Prostate cancer (PCa) ranks second in terms of cancer-related deaths among men in the
United States. The primary cause is the emergence of castration resistant prostate cancer …

In a truly innovative discovery, the inventors have found that psoriasis might be orally
treatable with the gastroprokinetic, mosapride, and other 5-HT4 receptor agonists. While it is …

From the prospective radical prostatectomy database maintained by Dr. Kryvenko, we
obtained patient samples from treatment naı̈ve and salvage radical prostatectomies with …

From the prospective radical prostatectomy database maintained by Dr. Kryvenko, we
obtained patient samples from treatment naı̈ve and salvage radical prostatectomies with …

Traditional de novo drug discovery, which typically presents an 11% approval rate from
phase I trials and even higher failure rates in fields like neurodegeneration, often requires …

Background: Desmopressin (d-amino d-arginine vasopressin: dDAVP) is used for the
treatment of patients with hemophilia A and Von Willebrand disease. Studies on the …

Repurposing off-patent drugs has long been proposed as a cost-effective and efficient
strategy to develop new treatments, but its potential has not been realized. Here, we …